Nothing Special   »   [go: up one dir, main page]

MA27905A1 - PYRAZOLINES AS ANTAGONISTS PAR-1 FOR THE TREATMENT OF CARDIOVASCULAR DISEASES - Google Patents

PYRAZOLINES AS ANTAGONISTS PAR-1 FOR THE TREATMENT OF CARDIOVASCULAR DISEASES

Info

Publication number
MA27905A1
MA27905A1 MA28710A MA28710A MA27905A1 MA 27905 A1 MA27905 A1 MA 27905A1 MA 28710 A MA28710 A MA 28710A MA 28710 A MA28710 A MA 28710A MA 27905 A1 MA27905 A1 MA 27905A1
Authority
MA
Morocco
Prior art keywords
pyrazolines
treatment
cardiovascular diseases
par
antagonists
Prior art date
Application number
MA28710A
Other languages
French (fr)
Inventor
Swen Allerheiligen
Dirk Brohm
Nicole Diedrichs
Britta-Nicole Frohlen
Christoph Gerdes
Mark Jean Gnoth
Heike Heckroth
Walter Hubsch
Elisabeth Perzborn
Elke Stahl
Verena Vohringer
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004010545A external-priority patent/DE102004010545A1/en
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of MA27905A1 publication Critical patent/MA27905A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des pyrazolines de formule (I) dans laquelle E désigne méthylène, NH désigne un atome d'oxygène ou un atome de soufre, R2 désigne un groupe de formule (II). L'invention concerne également des procédé permettant de produire lesdites pyrazolines et leur utilisation pour préparer des médicaments utilisés dans le traitement et/ou la prophylaxie de pathologies, notamment de maladies cardio-vasculaires, comme par ex. des maladies thromboemboliques.The invention relates to pyrazolines of formula (I) in which E denotes methylene, NH denotes an oxygen atom or a sulfur atom, R2 denotes a group of formula (II). The invention also relates to processes for producing said pyrazolines and their use for preparing medicaments used in the treatment and / or prophylaxis of pathologies, in particular cardiovascular diseases, such as e.g. thromboembolic diseases.

MA28710A 2003-07-15 2006-01-06 PYRAZOLINES AS ANTAGONISTS PAR-1 FOR THE TREATMENT OF CARDIOVASCULAR DISEASES MA27905A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10331951 2003-07-15
DE102004010545A DE102004010545A1 (en) 2003-07-15 2004-03-04 pyrazolines

Publications (1)

Publication Number Publication Date
MA27905A1 true MA27905A1 (en) 2006-05-02

Family

ID=34081645

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28710A MA27905A1 (en) 2003-07-15 2006-01-06 PYRAZOLINES AS ANTAGONISTS PAR-1 FOR THE TREATMENT OF CARDIOVASCULAR DISEASES

Country Status (8)

Country Link
EP (1) EP1648447A1 (en)
AU (1) AU2004257406A1 (en)
BR (1) BRPI0412554A (en)
CA (1) CA2532316A1 (en)
MA (1) MA27905A1 (en)
MX (1) MXPA06000507A (en)
NO (1) NO20060733L (en)
WO (1) WO2005007157A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004061747A1 (en) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Thiophene-substituted pyrazolines
DE102004061748A1 (en) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Azetidine-substituted pyrazolines
DE102004061751A1 (en) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Cyanoguanidine-substituted pyrazolines
JP2017538697A (en) * 2014-12-08 2017-12-28 バイエル ファーマ アクチエンゲゼルシャフト Novel aryl-cyanoguanidine compounds
US20180099937A1 (en) 2015-04-17 2018-04-12 Bayer Pharma Aktiengesellschaft Novel aryl-cyanoguanidine compounds
EP3283478A1 (en) * 2015-04-17 2018-02-21 Bayer Pharma Aktiengesellschaft Novel aryl-cyanoguanidine compounds
EP3109237A1 (en) 2015-06-22 2016-12-28 AnaMar AB Novel 5-ht2 antagonists
CN111892585A (en) * 2020-08-05 2020-11-06 杭州维坦医药科技有限公司 N-formamido pyrazoline derivative as P2X3 receptor antagonist and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466408B1 (en) * 1990-07-13 2000-01-12 Rohm And Haas Company N-aryl-3-aryl-4-substituted-4,5-dihydro-1H-pyrazole-1-carboxamides and processes for their production
DE4217862A1 (en) * 1991-08-28 1993-03-04 Bayer Ag SUBSTITUTED PYRAZOLINE
DE4217863A1 (en) * 1991-08-28 1993-03-04 Bayer Ag SUBSTITUTED PYRAZOLINE
DE4217864A1 (en) * 1992-05-29 1993-12-02 Bayer Ag Substituted pyrazolines
DE4233713A1 (en) * 1992-10-07 1994-04-14 Bayer Ag Substituted 4,5-dihydro-1-pyrazolecarboxanilides

Also Published As

Publication number Publication date
NO20060733L (en) 2006-04-10
AU2004257406A1 (en) 2005-01-27
BRPI0412554A (en) 2006-09-19
WO2005007157A1 (en) 2005-01-27
CA2532316A1 (en) 2005-01-27
EP1648447A1 (en) 2006-04-26
MXPA06000507A (en) 2006-04-05

Similar Documents

Publication Publication Date Title
MA27905A1 (en) PYRAZOLINES AS ANTAGONISTS PAR-1 FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
EA200600294A1 (en) [1,8] NAFTYRIDIN-2-ONE AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA
ATE440087T1 (en) 2,4-DIAMINOPYRIMIDENE DERIVATIVES THAT ARE SUITABLE AS INHIBITORS OF PKC-THETA
MA27675A1 (en) PIPERAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES
MA30914B1 (en) SUBSTITUTED DIHYDROPYRAZOLONES FOR THE TREATMENT OF CARDIOVASCULAR AND HEMATOLOGICAL DISEASES.
MY138478A (en) Benzazepine derivatives for the treatment of neurological disorders
MA29652B1 (en) SUBSTITUTED 7-AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PROCESS FOR PRODUCTION AND USE
MA27933A1 (en) INHIBITORS OF AKT ACTIVITY
BRPI0410905A (en) p-38 inhibitors
MXPA03011484A (en) Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease.
TR200101709T2 (en) Compounds useful in the treatment of inflammatory diseases
MA27668A1 (en) 2,4-DI (PHENYLAMINO) PYRIMIDINES USED TO TREAT NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS
AP2001002088A0 (en) 4,4-Biarylpiperidine derivatives with opiod receptor activity.
MA27769A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, their preparation and their therapeutic application
TNSN07167A1 (en) SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE
TW200503710A (en) Novel compounds
GB0111186D0 (en) Novel compounds
TNSN99031A1 (en) NOVEL HETEROCYCLIC COMPOUNDS INHIBITORS OF ROMATASES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ATE218342T1 (en) USE OF RIFAXIMIN AS A MEDICATION FOR THE TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIOSIS
MA28562B1 (en) 1,3,4-OXADIAZOL-2-ONES AS MODULATORS OF PPAR DELTA AND THEIR USE
SE0104331D0 (en) Novel compounds
GB0420831D0 (en) Novel compounds
DE60210614D1 (en) MACROCYCLES SUITABLE FOR THE TREATMENT OF ALZHEIMER DISEASE
GB0322510D0 (en) Novel compounds
GB0320320D0 (en) Novel compounds